BridgeBio Pharma Enters Material Definitive Agreement
Ticker: BBIO · Form: 8-K · Filed: Jul 2, 2025 · CIK: 1743881
| Field | Detail |
|---|---|
| Company | Bridgebio Pharma, Inc. (BBIO) |
| Form Type | 8-K |
| Filed Date | Jul 2, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation
TL;DR
BridgeBio just signed a big deal, expect financial moves.
AI Summary
On June 27, 2025, BridgeBio Pharma, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, incorporated in Delaware, is headquartered in Palo Alto, California.
Why It Matters
This filing indicates a significant new financial commitment or obligation for BridgeBio Pharma, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements can introduce new financial obligations or risks that may not be fully disclosed in the initial filing.
Key Players & Entities
- BridgeBio Pharma, Inc. (company) — Registrant
- June 27, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Palo Alto, CA (location) — Principal Executive Offices
FAQ
What type of material definitive agreement did BridgeBio Pharma, Inc. enter into?
The filing states that BridgeBio Pharma, Inc. entered into a material definitive agreement, creating a direct financial obligation or an obligation under an off-balance sheet arrangement of a registrant. Specific details of the agreement are not provided in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 27, 2025.
What is BridgeBio Pharma, Inc.'s state of incorporation?
BridgeBio Pharma, Inc. is incorporated in Delaware.
Where are BridgeBio Pharma, Inc.'s principal executive offices located?
BridgeBio Pharma, Inc.'s principal executive offices are located at 3160 Porter Dr., Suite 250, Palo Alto, CA 94304.
What is the SEC file number for BridgeBio Pharma, Inc.?
The SEC file number for BridgeBio Pharma, Inc. is 001-38959.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 2, 2025 regarding BridgeBio Pharma, Inc. (BBIO).